Revolution Medicines announced positive Phase 3 RASolute 302 trial results for daraxonrasib, an oral RAS(ON) inhibitor, in previously treated metastatic pancreatic cancer. The drug demonstrated a 60% reduction in death risk and doubled median overall survival to 13.2 months compared to 6.6 months with standard chemotherapy, with a manageable safety profile. Results were presented at ASCO 2026 and published in The New England Journal of Medicine.

Law firm Bragar Eagel & Squire is investigating Erasca, Inc. following a patent infringement allegation from Revolution Medicines regarding the company's ERAS-0015 drug candidate. The disclosure triggered a significant stock price decline of approximately 48%, dropping from $19.15 to $9.90 per share on April 28, 2026. The firm is seeking stockholders who suffered losses to discuss potential legal claims.

Revolution Medicines' experimental pancreatic cancer drug daraxonrasib has generated significant demand from cancer centers following FDA approval of its expanded access program in May. The Phase 3 RASolute 302 trial showed the drug doubled overall survival to 13.2 months versus 6.7 months for standard chemotherapy. However, the company faces operational challenges managing the compassionate use process, and RVMD stock declined 3.47% despite the positive clinical results.

Law firm Bragar Eagel & Squire is investigating Erasca, Inc. following a patent infringement allegation from Revolution Medicines regarding the company's ERAS-0015 drug candidate. The disclosure triggered a significant stock price decline of approximately 48%, dropping from $19.15 to $9.90 per share on April 28, 2026. The firm is seeking stockholders who suffered losses to discuss potential legal claims.

The Schall Law Firm is investigating Erasca, Inc. (NASDAQ: ERAS) for potential securities law violations following the company's disclosure on April 28, 2026, that it received a patent infringement letter from Revolution Medicines regarding its ERAS-0015 drug candidate, along with trade secret misappropriation allegations. The announcement triggered a 48.3% stock price decline on the same day.

Revolution Medicines announced the publication of Phase 1/2 clinical trial data for daraxonrasib in the New England Journal of Medicine, showing promising antitumor activity and durable responses in previously treated metastatic RAS mutant pancreatic cancer. The data supported initiation of the Phase 3 RASolute 302 trial, which recently reported unprecedented overall survival benefits compared to standard chemotherapy.

Both SCHA and ISCB are low-cost small-cap ETFs with identical 0.04% expense ratios, but differ in size, liquidity, and sector allocation. SCHA is larger with $22B in assets and leans toward Technology, while ISCB has $268.5M in assets with stronger Healthcare and Industrials exposure. Over 5 years, SCHA delivered higher returns (47.1% vs 38.4%), though the performance gap is modest. The choice depends on existing portfolio exposure and risk tolerance for 30% drawdowns.

Revolution Medicines announced updated Phase 1 clinical data for zoldonrasib, an oral RAS G12D-selective inhibitor, showing a 52% objective response rate and 93% disease control rate in previously treated KRAS G12D non-small cell lung cancer patients. The drug demonstrated a manageable safety profile with mostly Grade 1 adverse events and a favorable 94% mean dose intensity, supporting continued development in monotherapy and combination settings.

A wave of momentum swept through large-cap stocks during the week of April 13-17, 2026, with ten standout performers. Notable gainers include Avis Budget Group (71.48% jump driven by short squeeze), IonQ (62.86% surge following DARPA contract award), Oklo (33.35% rise on nuclear power narrative), Robinhood (33.22% gain from bullish analyst outlook and crypto rebound), and Strategy Inc (31.86% increase). Other top performers include Tempus AI, Credo Technology, Affirm Holdings, and Summit Therapeutics, with gains ranging from 28-31%.

Revolution Medicines, Inc. (NASDAQ: RVMD) announced the successful closing of concurrent upsized public offerings, raising approximately $2.2 billion in gross proceeds. The offerings included 12.1 million shares of common stock at $142.00 per share and $500 million in convertible senior notes due 2033 with a 0.50% interest rate. The company plans to use the net proceeds of approximately $2.1 billion for research and development, commercialization expenses, and general corporate purposes.

Revolution Medicines announced the pricing of concurrent public offerings totaling $2.0 billion, consisting of 10.56 million shares of common stock at $142.00 per share ($1.5 billion) and $500 million in 0.50% convertible senior notes due 2033. The offerings were upsized from previously announced amounts. Net proceeds will be used for R&D, commercialization, and general corporate purposes.

Revolution Medicines shares surged 39.97% in premarket trading following positive Phase 3 RASolute 302 trial results showing its drug daraxonrasib doubled overall survival (13.2 months vs. 6.7 months) compared to standard chemotherapy for metastatic pancreatic cancer. The company plans regulatory submissions and will present findings at the 2026 ASCO Annual Meeting. However, Merck ended acquisition discussions with Revolution Medicines over valuation disagreements.